184 related articles for article (PubMed ID: 35802877)
1. The role of circulating tumor DNA in evaluating minimal residual disease in luminal gastrointestinal malignancies.
Ueberroth BE; Jones JC; Bekaii-Saab T
Clin Adv Hematol Oncol; 2022 Jul; 20(7):444-455. PubMed ID: 35802877
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma.
Ueberroth BE; Jones JC; Bekaii-Saab TS
Pancreatology; 2022 Sep; 22(6):741-748. PubMed ID: 35725696
[TBL] [Abstract][Full Text] [Related]
3. [Research progress on circulating tumor DNA as a biomarker for minimal residual disease in solid tumors].
Chen Y
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Oct; 25(10):1072-1077. PubMed ID: 37905766
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W
BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of gastrointestinal carcinoma via molecular residual disease with circulating tumor DNA using a tumor-informed assay.
Qi Z; Li Y; Wang Z; Tan X; Zhou Y; Li Z; Zhao W; Zheng X; Yao J; Li F; Wang W; Wang Z; Pang F; Wang G; Gu W
Cancer Med; 2023 Aug; 12(16):16687-16696. PubMed ID: 37602656
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA minimal residual disease in clinical practice of non-small cell lung cancer.
Xia J; Zhang J; Xiong Y; Zhao J; Zhou Y; Jiang T; Zhu J
Expert Rev Mol Diagn; 2023; 23(10):913-924. PubMed ID: 37702546
[TBL] [Abstract][Full Text] [Related]
7. Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.
Moding EJ; Nabet BY; Alizadeh AA; Diehn M
Cancer Discov; 2021 Dec; 11(12):2968-2986. PubMed ID: 34785539
[TBL] [Abstract][Full Text] [Related]
8. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
Chen H; Zhou Q
Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers.
Alese OB; Cook N; Ortega-Franco A; Ulanja MB; Tan L; Tie J
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-20. PubMed ID: 35471832
[TBL] [Abstract][Full Text] [Related]
10. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer.
Bent A; Raghavan S; Dasari A; Kopetz S
Clin Colorectal Cancer; 2022 Jun; 21(2):89-95. PubMed ID: 35450837
[TBL] [Abstract][Full Text] [Related]
11. ctDNA as promising tool for the assessment of minimal residual disease (MRD) and the need of an adjuvant treatment in gastroesophageal adenocarcinoma.
Piva VM; De Grandis MC; Zuin IS; Angerilli V; Nappo F; Alfieri R; Ahcene Djaballah S; Murgioni S; Bergamo F; Fassan M; Valmasoni M; Lonardi S
Updates Surg; 2023 Feb; 75(2):305-312. PubMed ID: 36272058
[TBL] [Abstract][Full Text] [Related]
12. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA
Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670
[TBL] [Abstract][Full Text] [Related]
13. Mind the target: circulating tumour DNA in gastrointestinal malignancies.
Fontana E; Ignatova E
Curr Opin Oncol; 2022 Jul; 34(4):395-402. PubMed ID: 35837709
[TBL] [Abstract][Full Text] [Related]
14. Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors.
Chen K; Shields MD; Chauhan PS; Ramirez RJ; Harris PK; Reimers MA; Zevallos JP; Davis AA; Pellini B; Chaudhuri AA
Mol Diagn Ther; 2021 Nov; 25(6):757-774. PubMed ID: 34725800
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer.
Li FQ; Cui JW
Crit Rev Oncol Hematol; 2022 Nov; 179():103800. PubMed ID: 36031171
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal ctDNA profiling in precision oncology and immunο-oncology.
Filis P; Kyrochristos I; Korakaki E; Baltagiannis EG; Thanos D; Roukos DH
Drug Discov Today; 2023 Apr; 28(4):103540. PubMed ID: 36822363
[TBL] [Abstract][Full Text] [Related]
17. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices.
Malla M; Loree JM; Kasi PM; Parikh AR
J Clin Oncol; 2022 Aug; 40(24):2846-2857. PubMed ID: 35839443
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
Croessmann S; Park BH
Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964
[TBL] [Abstract][Full Text] [Related]
19. Development of circulating tumour DNA analysis for gastrointestinal cancers.
Nakamura Y; Shitara K
ESMO Open; 2020 Jan; 5(Suppl 1):e000600. PubMed ID: 32830648
[TBL] [Abstract][Full Text] [Related]
20. Going with the Flow: The Promise of Plasma-Only Circulating Tumor DNA Assays.
Bent A; Kopetz S
Clin Cancer Res; 2021 Oct; 27(20):5449-5451. PubMed ID: 34389607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]